Important information - Please remember the value of investments, and any income from them, can fall as well as rise so you could get back less than you invest. This article is provided to help you make your own investment decisions, it is not advice. If you are unsure of the suitability of an investment for your circumstances please seek advice. No news or research item is a personal recommendation to deal.
Fund research
AXA Framlington Biotech - takeover activity boosts performance
The AXA Framlington Biotech Fund aims to make the most of the opportunities on offer in one of the most interesting and exciting areas of the stock market. We review the fund’s performance and share our view on its prospects.
Published Feb 16, 2018
Published
Feb 16, 2018
Important information - This article isn’t personal advice. If you’re not sure whether an investment is right for you please seek advice. If you choose to invest the value of your investment will rise and fall, so you could get back less than you put in.
Written by
Dominic Rowles
Lead ESG Analyst
Dominic leads the team responsible for developing ESG integration across the business, and ensuring best practice is upheld.
Our content review process
The aim of Hargreaves Lansdown's financial content review process is to ensure accuracy, clarity, and comprehensiveness of all published materials
Article history
Published: 16th February 2018